|
Invention relates to functional food products and represents a method for production of a non-aqueous health-improving product that is administrated in the form of drops and contains strain of lactic bacteria suspended in vegetable food oil; vegetable food oil is mixed with vitamin D; Lactobacillus rhamnosus GG lactic bacteria are suspended in the produced oil mixture. |
|
|
Method of combination treatment of chronic endometritis in cows Aminoseleton is administered subcutaneously to animals in combination with symptomatic preparations - magestrofan, uteroton, tetragidrovit and etiotropic preparation. As etiotropic preparation the combination antimicrobial agent is used containing cefotaxime, neomycin, prednisolone, emulsifier, monoglyceride, vaseline oil, in the following ratio of components, wt %: cefotaxime - 7.0%, neomycin - 1.0%, prednisolone - 0.2%, emulsifier - 3.0%, monoglyceride - 1.0%, vaseline oil to 100.0, which is administered intrauterine 2-3 times with the 24-hour intervals in a dose of 20 ml. |
|
|
Bacterial strain lactobacillus acidophilus used to prepare fermented milk product Strain Lactobacillus acidophilus No. 9-PS has biochemical activity and high acidity. The strain is deposited in the Departmental collection of beneficial microorganisms for agricultural purposes of Russian Agricultural Academy (RCAM) under the registration number of RCAM01850. The strain may find application in prevention and correction of disorders of microbiocenosis of the gastrointestinal tract. |
|
|
Invention relates to industrial microbiology, namely to a method of obtaining a composition, intended for prevention of a cow milk protein allergy (CMPA) and a higher sensitivity to allergens in newborn babies and infants. The method includes a stage of milk substrate bioconversion by means of a culture of Bifidobacterium breve BBC50 strain, deposited on May 31 1999 in the National Collection of Cultures of Microorganisms (CNCM) under the number I-2219, by keeping a substrate in contact with the strain culture under conditions unfavourable for production of an acid by the strain. |
|
|
Prevention and treatment of allergic diarrhoea Invention relates to the pharmaceutical industry and represents application of a composition, containing Bifidobacterium breve CNCM I-3865 (NCC2950) for preparation of a composition for prevention of allergic diarrhoea. |
|
|
Using lactobacillus plantarum for providing bacterial diversity Invention refers to industrial microbiology, namely to creating of strain Lactobacillus plantarum specified in a group consisting of Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL-9, DSM 15312, Lactobacillus plantarum HEAL-19, DSM 15313, and Lactobacillus plantarum HEAL-99, DSM 15316, for increasing the gastrointestinal bacterial diversity. The above strains are applicable to prevent developing low bacterial diversity (LBD) in a healthy individual, to prevent developing translocation, large intestinal bacterial overgrowth (LIBO) or small intestinal bacterial overgrowth (SIBO) in the individual with LBD, to prevent developing translocation in the individual with LIBO or SIBO. |
|
|
Invention relates to a preparation for babies for reduction or prevention of inflammation in a baby. The preparation for babies includes a source of protein, providing from 1 to 5 g of protein per 100 kkal of the preparation, a source of fat or lipids, providing from 3 to 7 g of fat or lipids per 100 kkal of the preparation, a source of carbohydrates, providing from 8 to 12 g of carbohydrates per 100 kkal of the preparation, a source of long-chain polyunsaturated fatty acids, including docosahexaenoic acid. The preparation also includes from 1×104 CFU to 1×1010 CFU of Bifidobacterium longum AH1206 NCIMB 41382 per a gram of the preparation. Also claimed are probiotic baby food and a method of reduction or prevention of inflammation in the baby or child with application of the said food. |
|
|
Method of bacterial ghost (bg) Invention relates to biotechnology and represents a method of producing a bacterial ghost preparation, a pharmaceutical composition, which is a vaccine or an adjuvant, a method of inactivating live bacterial cells in the bacterial ghost preparation and application of beta-propiolactone. The method includes obtaining the bacterial ghost preparation and processing the bacterial ghost preparation with beta-propiolactone in a final concentration from 0.01% to 1% (vol/vol), at which the quantity of live bacterial cells in the said ghost preparation reduces by at least 103-104. The pharmaceutical composition includes efficient quantity of the bacterial ghost preparation, processed with beta-propiolactone in a final concentration from 0.01% to 1% (vol/vol), and a pharmaceutically acceptable carrier, a diluent and/or an adjuvant. |
|
|
1 glass of an aqueous infusion of swallowwort herb or garden sage herb is orally administered daily on an empty stomach in the morning 1-2 hours before meals for 10 days. That is followed by administering an aqueous infusion of camomile blossom daily on an empty stomach for 10 days also. For the further 10 days, an aqueous infusion of plantain leaves is administered daily on an empty stomach; the infusions of chamomile blossom and plantain leaves are taken in a dose of 1/2 glass 3-5 times a day 30 minutes before meals. Administering the aqueous infusions is combined with orally daily administering an infusion of Saint-John's-wort for 30 days orally in a dose of 50 drops per 1/2 glass of water 3 times a day 30 minutes before meals. After that, the liquid biocomplex Normoflorin is orally administered 3 times a day daily for 4 weeks 30 minutes before meals in age doses. Normoflorin L is used for the first and second administration, and Normoflorin B - for the third one. |
|
|
Group of inventions relates to field of biotechnology. Strain Bifidobacterium breve MCC 1274 FERM BP-11175 demonstrates low coefficient of conversion of linoleic acid into conjugated linoleic acid. Strain demonstrates coefficient of conversion of linoleic acid into conjugated linoleic acid not higher than 10%. To reduce or prevent obesity or to improve tolerance to glucose said strain is introduced in efficient quantity to subject requiring it. Also claimed are food product and drink, which contain preparation based on said strain. |
|
Method provides for cultivation at 37±1°C of strains of lactobacilli and bifidobacteria in the medium and packing of liquid product with account of daily dose necessary for patients. The medium contains components in the following quantities: caseine hydrolysate dissolved by distilled water, 0.33-0.4 g/l, sodium chloride 5 g/l, fructose 10 g/l, peptone 2 g/l, agar-agar 0.75 g/l for lactobacilli, for bifidobacteria - 1.0 g/l, ascorbic acid 0.25 g/l, distilled water 0.67-0.6 g/l. Strains-producers are Lactobacillus plantarum 8 RA-3, Lactobacillus fermentum 39, Lactobacillus fermentum 90 TC-4, Bifidobacterium bifidum 791, Bifidobacterium longum 379, Bifidobacterium bifidum 1. For lactobacilli and bifidobacteria they prepare accordingly media with different content of agar-agar, amine nitrogen in caseine hydrolysate 160-170 and 180-200 mg% and medium pH 7.8-8.0 and 8.5-8.6. Starting from the first generation the bifidobacteria and lactobacilli are cultivated for 24±1 hours, two strains together, one separately. The produced biomass is mixed with the fresh nutrient medium at the ratio of 1:1000, and strains of lactobacilli are cultivated 24±1 hours, strains of bifidobacteria - 48±1 hours. Upon completion of cultivation of biomass of strains they are mixed at the ratio of 2:1:2:1. |
|
Nourishing composition, including probiotics and improving sleep pattern Invention relates to application of probiotic bacterial strain for production of a probiotic composition for reducing sleep disorders and/or improvement of sleep quality in people and animals. As a bacterial strain used is Lactobacillus reuteri DSM 17938 or Bifidobacterium longum NCC 3001 (ATCC BAA-999). |
|
Invention relates to versions of medication for reduction of halitosis, versions of compositions based on said medications and versions of application of said medications. Device for reduction of halitosis represents strains of microorganisms Lactobacillus acidophilus, selected from group Lactobacillus acidophilus DSM 19825, Lactobacillus acidophilus DSM 19826 and Lactobacillus acidophilus DSM 19827. Version of said medication represents culture supernatant of said strains. Also claimed are compositions, which contain said microorganisms, and their application for reduction of halitosis. |
|
Method of treating low-body-weight premature newborns Invention refers to medicine, particularly to paediatrics and neonatology, and can be used for treating small premature infants at the hospital stage of developmental care. A therapeutic complex comprises administering a probiotic preparation into the newborns. The preparation is presented with a liquid probiotic containing E.faecium L3 109 CFU in 1 ml. If the enteral nutrition volume of the newborn is 5 ml or more, this preparation is orally administered in a dose of 0.5 ml 3 times a day for 14 days. |
|
Method for preparing combined antibacterial preparation for treating acute intestinal infections Invention refers to medicine and biotechnology, and represents a method for preparing a combined antibacterial preparation for treating acute intestinal infections. The invention is to prepare a biological ingredient biomass representing a complex of immunoglobulins or bifidus bacteria biomass, to mix it with an antibiotic substance in specified proportions, and differs from the known analogues by the fact that mixing the two ingredients of the preparation is preceded by grinding the biological ingredient only to be ground to the greatest maximum bulk density of the ground material. |
|
|
Group of inventions relates to biotechnology and medicine. Disclosed is a polysaccharide which is isolated from the Bifidobacterium infantis NCIMB 41003 strain and has the structure [-β(1,3)-D-GalpNAc-β(1,4)-D-Glcp-]n, where said disaccharide unit repeats n times, which yields a polysaccharide with molecular weight greater than 100000 Da. The polysaccharide exhibits immunomodulating activity and is used in preparing medicinal agents for treating or preventing undesirable inflammatory activity, undesirable gastrointestinal inflammatory activity, rheumatoid arthritis and autoimmune disorders. |
|
Probiotic composition intended for babies with low body weight at birth Invention relates to compositions intended for babies with low body weight at birth. The probiotic composition intended for complete enteral nutrition of babies with body weight at birth being no more than 1500 g contains probiotic strains chosen from Lactobacillus rhamnosus, Lactobacillus reuteri, Bifidobacterium longum species or their mixtures. |
|
Method for normalising reproductive function Invention refers to medicine and can be used for normalising (improving, recovering, stimulating) the mammalian, especially human, reproductive function. That involves the oral administration of a preparation representing high-lactate milk whey (HLMW) that contains 7% of dry substances, including 5% of milk whey and 2% of sodium hydroxide, or ammonium carbonate, or calcium hydroxide prepared by hydrolysis of milk whey pasteurised at temperature 53-57°C in the culture environment of Lactobacillus acidophilum and Lactobacillus bulgaricum at culture temperature 36 to 40°C and neutralisation of formed lactic acid with sodium hydroxide, or ammonium carbonate, or calcium hydroxide to achieve a weight fraction of lactose no more than 0.2%. |
|
Starter material of pure growth of lactate microorganisms for preparation of cultured milk products Strain Lactococcus casei VKPM V-8730 is obtained at available growth-supporting media and is used as starter material in cultured milk products production. |
|
|
Starter material of pure growth of lactate microorganisms for preparation of cultured milk products Strain Enterococcus durans VKPM B-8731 is obtained at available growth-supporting medium and is used as starter material in cultured milk products production. |
|
|
Method for preparing autoprobiotic containing living bifidus bacteria and lactic acid bacilli Method for preparing an autoprobiotic containing living bifidus bacteria and lactic acid bacilli for the rehabilitation of human and animal intestinal microflora involves the recovery of living bifidus bacteria and lactic acid bacilli from a host's intestine and the use thereof in the form of automicroorganisms with the above bifidus bacteria and lactic acid bacilli recovered simultaneously in the form of a natural complex of indigenous microorganisms by dissolving the host's intestinal contents with a fluid with adding selective ingredient having no inhibitory action on the bifidus bacteria and lactic acid bacilli, adding a solution of the same host's saliva, culturing the mixture and inoculating a nutrient medium for culturing the bifidus bacteria and lactic acid bacilli with no selective agents added. |
|
|
Group of inventions refers to microbiology and biotechnology. Proposed strains Lactobacillus crispatus "ВКМ" B-2727D, Lactobacillus gasseri "ВКМ" B-2728D and Lactobacillus plantarum "ВКМ" B-2731D have antagonistic activity in relation to pathogenic and semi-pathogenic microorganisms. Besides, the invention proposes a consortium based on the above strains for production of a bacterial preparation, a biologically active additive, and direct inoculation for obtaining fermented milk product of functional nutrition. |
|
Method for pore formation in hepatocyte membranes by bacillus cereus hemolysin ii processing Invention refers to biotechnology and represents a method involving Bacillus cereus hemolysin (HlyII) hemolysin processing of primary membrane hepatocyte and determining the membrane permeability after HlyII processing. Substance of the presented invention consists in the fact that the action of the HlyII preparation on the cell membranes provides the more effective transport of various low-molecular compounds through the cell membranes. The object in view is to form nanometric pores in the hepatocyte membranes ensured by the action of the low concentration of the purified HlyII preparations on the primary hepatocytes. An increase of the hepatocyte membrane permeability after the HlyII preparation processing is determined by microspectral analysis of low-molecular fluorescent dyes. As observed, the increased permeability of the above dyes into the hepatocyte permeability characterises higher permeability of the processed hepatocyte membranes. |
|
|
Combined antibacterial preparation for treating acute intestinal infections Invention refers to medicine and biotechnology and concerns treating an antibacterial agent for treating gastrointestinal diseases, preferentially acute intestinal infections, including unexplained. The declared preparation represents a mixture of an antibiotic and probiotic, wherein the antibiotic is presented by ofloxacin, while the probiotic is a bifidus bacterial biomass in the following ratio, mg/capsule: ofloxacin - 200 mg, bifidus bacterial biomass - 200 mg containing min. 2×107 CFU/g living microorganisms. |
|
|
Bacillus licheniformis strain has antagonism in relation to Salmonella typhi, Staphylococcus aureus, Listeria monocytogenes and resistance to the following antibiotics: streptomycin and nalidixic acid. The strain is deposited with number BKM B-2712D in the All- Russian collection of microorganisms of the Institute of Biochemistry and Physiology of Microorganisms of the Russian Academy of Science (IBFM RAN). |
|
|
Strain is deposited in CNCM and has number 1-3689. Strain has ability to inhibit the growth of pathogenic microorganisms in culture, and namely Escherichia coli, Salmonella enteritidis and Listeria monocytogenes. Strain has anti-inflammatory properties at the ratio of IL-10/IL-12 equal to 11.8. |
|
Bacillus licheniformis VKM B-2713D strain has apparent antagonism in relation to Salmonella typhi, Staphylococcus aureus, Listeria monocytogenes. Strain has resistance to antibiotics at streptomycin concentration of 20 mcg/ml and at concentration of nalidixic acid of 20 mcg/ml. Strain has α-amylase activity of 0.015 U/ml of the medium at pH 6.0, protease activity of 2.34 U/ml of the medium at pH 7.0. |
|
|
Immunomodulatory extracts of bacteria lactobacillus and methods for preparing and using them Invention refers to pharmaceutical industry, namely to an extract of one or more bacterial strains Lactobacillus. The extract of one or more bacterial strains Lactobacillus representing a soluble extract, wherein the extract contains chemically modified bacterial molecules prepared by the action of an alkaline medium on one or more bacterial strains Lactobacillus; the extract is effective in treating diseases associated with the anti-inflammatory cytokine production imbalance. A method for preparing the extract of one or more bacterial strains Lactobacillus. A pharmaceutical composition effective for reducing at least one symptom associated with at least one condition specified in a respiratory disorder, an allergic condition, an urinary disorder and a gastric disorder, containing the extract. A nutritional composition. A pharmacological composition effective in treating the diseases associated with the anti-inflammatory cytokine production imbalance, containing the extract. A method of relieving the above symptoms. The extract prepared by the above method. |
|
Invention refers to medicine, namely gynaecology and may be used for individual selection of the preparations containing the probiotic lactic bacterial strains for effective intravaginal therapy. For this purpose, vaginal epithelial cells are recovered from the patient, released from the accompanying microflora. That is followed by preparing an epithelial cell suspension in a culture medium, and mixed with a suspension of thermally-activated probiotic lactic bacterial strains. Then, the suspension is incubated; the epithelial cell culture fluid filtrate is prepared and added to the suspension of the tested probiotic lactic bacterial strains in ratio 1:7. Concurrently, a reference of the mixture of the epithelial cell culture medium and the suspension of the tested probiotic lactic bacterial strains in ratio 1:7 is prepared. The test and reference samples are incubated, measured for optical density; and a degree of biomass increase in the test sample is related to that in the reference. The preparation containing the probiotic lactic bacterial strains the biomass increase of which under the influence of patient's vaginal epithelial cells is stimulated most is selected form the effective intravaginal therapy. |
|
Invention refers to pharmaceutics, namely to the application of a probiotic of the species Lactobacillus rhamnosus in preparing a composition for normalising a patient's pathological lipid profile, wherein the above profile comprises lysophospholipid and/or ceramide sphingolipid. A method for normalising the patient's pathological lipid profile by administering the probiotic of the species Lactobacillus rhamnosus in an amount sufficient to achieve the desired effect, into the patient. |
|
Method for stimulating intestinal flora Group of inventions refers to medicine, namely to paediatrics and may be used for preparing a composition for oral administration into an infant born by Cesarean section. This purpose is achieved by using at least one microorganism, and at least one nondigestible oligosaccharide. The composition contains at least one species Bifidobacteria specified in a group consisting of Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium catenulatum, Bifidobacterium adolescentis and Bifidobacterium longum and galactooligosaccharides as an oligosaccharide. What is also presented is a method for preparing the infant food suitable for the infant born by Cesarean section. |
|
|
Method for maintaining physiological status in newborn calves Method refers to veterinary science and aims at maintaining the physiological status in newborn calves. The method involves using the biologically active substance coredon. Coredon is pre-mixed with ascorbic acid. This mixture is dissolved in water, fed to calves in the amount of 2 g, once a day, from the second after-birth day for 5 days. |
|
|
Probiotics for improving tga secretion in infants born by caesarean section Invention refers to pharmaceutical industry and represents using probiotic bifidus bacteria in preparing a nutritional composition for improving IgA secretion in the infants born by cesarean section for the first four months of life. |
|
|
Invention relates to a synbiotic preparation containing N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine and a probiotic strain Lactobacillus sp. The oligosaccharide containing N-acetyl-lactosamine is lacto-N-tetraose or lacto-N-neotetraose. The probiotic strain Lactobacillus sp. is Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730 or Lactobacillus reuteri DSM 17938. |
|
|
Invention relates to biotechnology, agriculture and zootechnics and may be used for industrial-scale breeding of broiler chickens of highly productive crosses. Prolyser symbiotic preparation based on Escherichia coli VL-613 is activated by way of resuspension with cooled boiled water or sterile physical solution at a temperature of 25°C - 37°C. The preparation in a dissolved form is given to drink to broiler chicken during 1 hour after the preparation activation in accordance with the following scheme. From the 8th day since the chicken birth and to the 22nd day the preparation is given in an amount of 100 mln microbial cells per day (per 1 chicken of "Кобб-500" and "Авиан-48" crosses) or 50 mln microbial cells per day (per 1 chicken of "Смена-7" cross). From the 22nd day and up to broiler chickens growing completion the preparation is given in an amount of 75 mln microbial cells per day (per 1 chicken of "Кобб-500" and "Авиан-48" crosses) or 50 mln microbial cells per day (per 1 chicken of "Смена-7" cross). The preparation is administered orally, preferably - during the morning feeding. The concentration of Escherichia coli VL-613 is equal to 1.75-3.05 billion microbial cells of the preparation per 1 broiler chicken throughout the whole growing cycle. |
|
|
Controlled activation of reuterin induction Group of inventions refers to medicine and is used to preparing the cell cultures of Lactobacillus reuteri, containing reuterin to be kept inside the cells. The method involves the fermentation of cell cultures, the addition of 1,2-propanediol or glycerol to the reuterin-producing cell systems Lactobacillus reuteri in the beginning of the fermentation, the addition of glycerol to the cell cultures of Lactobacillus reuteri during the production and preservation of the cells Lactobacillus reuteri. The product prepared by the declared method contains the kept cells Lactobacillus reuteri with reuterin kept in the cells. |
|
Method for relieving abdominal murmur by introducing bacteria of genus bifidobacterium Invention refers to medicine and may be used for relieving abdominal murmur. That is ensured by the oral administration of the bacteria Bifidobacterium animalis in dose 1×109 CFU a day. The bacteria are administered every day, for at least 15 days. |
|
Method of preventing and treating oral inflammation following dental surgery Invention refers to pharmaceutics and represents a method of preventing and treating oral inflammation following a dental surgery, comprising in applying a drug preparation on an incisional wound daily in a patient underwent the implantation procedure and characterised by the fact that the drug preparation used represents a preparation of the strain lactobacillus plantarum 8P-AZ and/or B.bifidum in a dose of at least 10 million live lactic acid bacilli and/or bifidus bacteria. |
|
Method for reducing abdominal girth by administering bacteria bifidobacterium Invention refers to medicine, and aims at reducing an abdominal girth in an individual. The bacteria of genus the Bifidobacterium are used. A minimum dose is 1×109 CFU a day. Preferentially, the bacteria represent the bacteria of the genus Bifidobacterium animaiis deposed under Nos. CNCM I-2494. The abdominal girth is measured using abdominal inductance plethysmography. The method may be used for treating irritable bowel syndrome. |
|
Bifidobacterial and lactobacillary consortium contains Bifidobacterium bifidum OV-19, B. bifidum 791, B. longum OV-20, B. longum"Я"-3, B. adolescentis "ГО"-13, Lactobacillus helveticus "К3ш24", L. helveticus NK-1, L. casei KHM-12; it is used for preparing bacterial preparations and dietary supplements for correcting the microflora in the individuals of fourteen and older. The consortium is high-technology; it stores a biomass on nutrient mediums over a short period of time with a high concentration of probiotic microorganisms, possesses the acid-forming and antagonist properties in relation to the pathogenic and opportunistic microflora. The consortium is prepared by the co-culture of the strains including the length of an exponential growth phase of each of them whereby a priority of the nutrient medium inoculation of the specific composition is determined. |
|
|
Bifidobacterial and lactobacillary consortium contains Bifidobacterium bifidum 19, B. bifidum 791, B. longum B379M, B. longum OV-20, B. breve OV-12, L .helveticus "К3Ш24", L. helveticus NK-1, L. casei KHM-12; it is used for preparing bacterial preparations and dietary supplements for correcting the microflora in the children aged from three to fourteen. The consortium is high-technology; it stores a biomass on nutrient mediums over a short period of time with a high concentration of probiotic microorganisms, possesses the acid-forming and antagonist properties in relation to the pathogenic and opportunistic microflora. The consortium is prepared by the co-culture of the strains including the length of an exponential growth phase of each of them. Thereby a priority of the nutrient medium inoculation of the specific composition is determined. |
|
|
Bifidobacterial consortium contains Bifidobacterium bifidum OV- 19, B. bifidum 791, B. longum B379M, B. longum OV-20, B. breve OV-12; it is used for preparing bacterial preparations and dietary supplements for correcting the microflora in the children aged from three to fourteen. The consortium is high-technology; it stores a biomass on nutrient mediums over a short period of time with a high concentration of probiotic microorganisms, possesses the acid-forming and antagonist properties in relation to the pathogenic and opportunistic microflora. The consortium is prepared by the co-culture including the length of an exponential growth phase of each of them whereby a priority of the nutrient medium inoculation of the specific composition is determined. |
|
Bifidobacterial consortium contains Bifidobacterium bifidum OV-19, B. bifidum 791, B. longum B379M, B. breve OV-12, B. Mantis 73-15; it is used for preparing bacterial preparations and dietary supplements for correcting the microflora in the children under the age of three. The consortium is high-technology; it stores a biomass on nutrient mediums over a short period of time with a high concentration of probiotic microorganisms, possesses the acid-forming and antagonist properties in relation to the pathogenic and opportunistic microflora. The consortium is prepared by the co-culture of the strains including the length of an exponential growth phase of each of them whereby a priority of the nutrient medium inoculation of the specific composition is determined. |
|
Bifidobacterial consortium contains Bifidobacterium bifidum OV-19, B. bifidum 791, B. longum OV-20, B. longum "Я"-3, B. adolescentis "ГО"-13; it is used for preparing bacterial preparations and dietary supplements for correcting the microflora in the individuals of fourteen and older. The consortium is high-technology; it stores a biomass on nutrient mediums over a short period of time with a high concentration of probiotic microorganisms, possesses the acid-forming and antagonist properties in relation to the pathogenic and opportunistic microflora. The consortium is prepared by the co-culture of the strains including the length of an exponential growth phase of each of them whereby a priority of the nutrient medium inoculation of the specific composition is determined. |
|
Bifidobacterial and lactobacillary consortium contains Bifidobacterium bifidum OV-19, B.bifidum 791, B.longum B379M, B.breve OV-12, B.infantis 73-15, Lactobacillus helveticus "К3ш24", L.helveticus NK-11, L.casei KHM-12; it is used for preparing bacterial preparations, as a part of dietary supplements for correcting the microflora in the children under the age of three. The consortium is high-technology; it stores a biomass on nutrient mediums over a short period of time with a high concentration of probiotic microorganisms, possesses the acid-forming and antagonist properties in relation to the pathogenic and opportunistic microflora. The consortium is prepared by the co-culture of the strains including the length of an exponential growth phase of each of them. Thereby a priority of the nutrient medium inoculation of the specific composition is determined. |
|
Invention refers to pharmaceutics, namely to a composition for preventing and/or treating respiratory pathologies and/or infections and for improving intestinal functions. Using a symbiotic composition for preparing a drug preparation for preventing and/or treating the respiratory pathologies and/or infections. The symbiotic composition containing an active ingredient presented by a) a mixture containing the following bacterial strains: Lactobacillus plantarum LMG P-21020; Lactobacillus plantarum LMG P-21021; Lactobacillus rhamnosus DSM 16605; Lactobacillus rhamnosus DSM 19739; Bifidobacterium lactis LMG P-21384 and b) a prebiotic ingredient containing at least one scFOS (short-chain fructooligosaccharide) or GOS (galactooligosaccharide). |
|
Invention refers to pharmaceutical industry, particularly to using probiotics in the manufacture of a drug or a therapeutic nutritional composition for long-term prevention of diarrhea in infants. Using the probiotic Lactobacillus rhamnosus ATCC 53103 or Lactobacillus rhamnosus CGMCC 1.3724, and the probiotic Bifidobacterium longum ATCC BAA-999 in the manufacture of a drug or a therapeutic nutritional composition to be introduced into an infant for at least three months for the purpose of long-term prevention of diarrhoea, wherein the probiotic is introduced into a breastfeeding infant from a nursing mother. |
|
|
Composite probiotic preparation and method for preparing it Invention refers to pharmaceutical industry, and represents a composite probiotic preparation containing probiotic lactic acid bacilli and bifidus bacteria cells, or mixtures thereof, and a polymer additive in an enterosoluble capsule, differing by the fact that the probiotic lactic acid bacilli and bifidus bacteria cells belong to the species Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Bifidobacterium longum, while the polymer additive used as a binding agent and being a polysaccharide, is specified in a group: amylopectin, waxy corn starch, native potato starch, soluble potato starch, wheat starch, maltodextrin, or mixtures thereof with the above ingredients of the composite preparation are taken in ratio 108-1012 probiotic lactic acid bacilli and bifidus bacteria cells per 0.01-1 g of the polymer additive. |
|
Using lactobacillus paracasei cncm i-2116 to treat irritable bowel syndrome Invention relates to use of the Lactobacillus paracasei CNCM I-2116 strain to treat irritable bowel syndrome. A probiotic includes dead Lactobacillus paracasei CNCM I-2116 bacteria, a fermentation substrate and/or material made from Lactobacillus paracasei CNCM I-2116. |
|
Presented inventions refer to immunology, and concern methods and compositions for preventing or treating conjunctivitis associated with feline herpes virus-I (FHV-I). The used composition contains the strain Enterococcus faecium NCIMB 10415 (SF68) in the amount at least approximately 102-1011 CFU per one gram of the composition. The methods consist in administering such composition to an animal. |
Another patent 2513868.